Australia's most trusted
source of pharma news
Posted 24 November 2024 AM
The TGA has listed five new drugs on the ARTG, with at least three of them destined for blockbuster status around the globe.
Novartis' radioligand Lutathera, which recently achieved blockbuster status, has been approved by the TGA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumours in adults. A similar radioligand has been listed on the MBS without being listed on the ARTG, the same situation Novartis had to deal with concerning Pluvicto.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.